13 June 2019 - - US-based regenerative medicine and cell therapy company InGeneron, Inc has extended its Series D financing by up to USD 23m, totaling up to USD 43m to be invested in the organization, the company said.
The additional funds will come from InGeneron's clinical partner Sanford Health, one of the largest integrated health systems in the United States. The investment is structured in various tranches linked to progress in the company's development.
It will support the advancement of InGeneron's pivotal study in rotator cuff tendinopathy, a degenerative and often chronic condition found in a person's shoulder, as well as other clinical programmes in its autologous point-of-care cell therapy portfolio.
Last month, the company announced the enrollment of the first patients in its rotator cuff tendinopathy pivotal trial.
InGeneron's therapeutic approach involves isolating and preparing adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue and administering the cells locally at the site of injury.
The therapy is enabled by a proprietary cell processing system, designed for a one-time, minimally-invasive, outpatient procedure performed at the bedside. The company's primary focus is on developing an autologous cell therapy to treat pain and functional impairments associated with musculoskeletal conditions.
InGeneron has launched three clinical programs centered around key musculoskeletal conditions. Its lead programme in partial thickness rotator cuff tears is presently enrolling patients in a double-blinded, multi-center pivotal study.
The company is also conducting feasibility trials in chronic back pain and wrist osteoarthritis.
It reported top-line data of its partial thickness rotator cuff tear feasibility study in December 2018, which found the therapy to be safe and well-tolerated.
The data can be found on the company's website, and the results of that trial are being prepared for peer-reviewed publication.
InGeneron is a clinical stage cell therapy company enabling novel, safe and evidence-based regenerative medicine therapies.
Our purpose is to set new therapeutic standards by developing treatments that unlock the healing potential of each patient's own regenerative cells processed at the point of care for same-day application. We focus on helping patients who are impacted by musculoskeletal conditions. 
Sanford Health, one of the largest health systems in the United States, is dedicated to the integrated delivery of health care, genomic medicine, senior care and services, global clinics, research and affordable insurance.
Headquartered in Sioux Falls, South Dakota, the organisation includes 44 hospitals, 1,400 physicians and more than 200 Good Samaritan Society senior care locations in 26 states and nine countries.
Nearly USD1 bn in gifts from philanthropist Denny Sanford have transformed how Sanford Health improves the human condition.